1.Name and nature of the underlying assets (if preferred shares,the terms and conditions of issuance shall also be indicated,e.g., dividend yield, etc.):Common shares of Chuang Yi Biotech Co., Ltd. 2.Date of occurrence of the event:2023/11/02 3.Volume, unit price, and total monetary amount of the transaction: (1)Volume:17,000,000 shares is the upper limit. (2)Unit price:NTD 10 per share. (3)Total monetary amount:NTD 170,000,000 is the upper limit. (4)The Company subscribes for shares according to the original shareholding ratio. If employees and other shareholders of Chuang Yi Biotech Co., Ltd. giveup subscription, the Company can subscribe for shares as a specific person. The total number of subscirbed shares and the amount are limited to 17,000,000 shares and NTD 170,000,000. 4.Trading counterparty and its relationship to the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): The Company's other related party. 5.Where the trading counterparty is a related party,announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary value of transfer:NA. 6.Where an owner of the underlying assets within the past five years has been an related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship to the Company at the time of the transaction:NA. 7.Matters related to the current disposal of creditors’ rights (including types of collaterals of the disposed creditor’s rights; if creditor’s rights over a related party, announcement shall be made of the name of the related party and the book amount of the creditor's rights, currently being disposed of, over such related party:NA. 8.Profit or loss from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status of recognition shall be listed and explained):NA. 9.Terms of delivery or payment (including payment period and monetary value), restrictive covenants in the contract, and other important terms and conditions: (1)Terms of payment:Based on the actual investment schedule of Chuang Yi Biotech Co., Ltd. and the amount are limited to NTD 170,000,000. (2)Restrictive covenants in the contract, and other important terms and conditions:None. 10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making unit: (1)The reference basis for the decision on price:The appraisal report of Chuang Yi Biotech Co., Ltd. issued by China Intangible Asset Appraisement Co., Ltd. The Company has also referred to the opinion of reasonableness of the transaction price issued by Chainye Accounting Firm. (2)Decision-making unit:BOD of the Company 11.Net worth per share of the Company’s underlying securities acquired or disposed of:NTD 4.07 12.Cumulative no.of shares held (including the current transaction), their monetary value, shareholding percentage,and status of any restriction of rights (e.g., pledges),as of the present moment: (1)Cumulative no. of shares held:17,589,293 is the upper limit. (2)Monetary value:NTD 210,251,700 is the upper limit. (3)Shareholding percentage:54.71% is the upper limit. (4)Status of any restriction of rights:None. 13.Ratio of securities investment (including the current transaction) to the total assets and shareholder’s equity of the parent company on the latest financial statements, and the operating capital on the latest financial statements, as of the present moment: (1)Ratio of securities investment to the total assets:37.23% is the upper limit. (2)Ratio of securities investment to the total shareholder's equity:39.75% is the upper limit. (3)Operating capital:NTD 833,235 thousands. 14.Broker and broker’s fee:NA. 15.Concrete purpose or use of the acquisition or disposal: Chuang Yi Biotech Co., Ltd. has put a lot of effort into clinics and pharmacies channels for many years and has focused on out-of-pocket vaccines and preventive healthcare promotion in recent years. There are no overlaps between the products of the two parties. It is expected that the cooperation between the two parties will expand the sales channels and the categories of diseases. 16.Whether the directors expressed any objection to the current transaction:No. 17.Whether the counterparty of the current transaction is a related party:Yes. 18.Date of the Board of Directors’ resolution:2023/11/02 19.Date of ratification by supervisors or approval by the Audit Committee:2023/11/02 20.Whether the CPA issued an opinion on the unreasonableness regarding the current transaction:No. 21.Name of the CPA firm:Chainye Accounting Firm 22.Name of the CPA:Pi-Chia Lin CPA 23.License no.of the CPA:SFC Certificate No. 5800 24.Any other matters that need to be specified: The net worth per share of Chuang Yi Biotech Co., Ltd. on June 30, 2023 is NTD 4.07, the gap from the transaction price of NTD 10 per share is more than 20%. However, the BOD of Chuang Yi Biotech Co., Ltd. resolved the reduction of capital on April 18, 2023, the case had been admitted by the shareholders' meeting on May 30, 2023 and had been approved by Taipei City Hall on August 15, 2023. The net worth per share after reduction of capital is NTD 9.13.